These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 3288653)

  • 1. Amphetamine, but not methylphenidate, predicts antidepressant efficacy.
    Little KY
    J Clin Psychopharmacol; 1988 Jun; 8(3):177-83. PubMed ID: 3288653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. d-Amphetamine versus methylphenidate effects in depressed inpatients.
    Little KY
    J Clin Psychiatry; 1993 Sep; 54(9):349-55. PubMed ID: 8407854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine.
    Kuczenski R; Segal DS
    J Pharmacol Exp Ther; 2001 Mar; 296(3):876-83. PubMed ID: 11181919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization and cross-sensitization after chronic treatment with methylphenidate in adolescent Wistar rats.
    Valvassori SS; Frey BN; Martins MR; Réus GZ; Schimidtz F; Inácio CG; Kapczinski F; Quevedo J
    Behav Pharmacol; 2007 May; 18(3):205-12. PubMed ID: 17426484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminative stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans.
    Stoops WW; Lile JA; Glaser PE; Rush CR
    Exp Clin Psychopharmacol; 2005 Feb; 13(1):56-64. PubMed ID: 15727504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule.
    O'Donnell JM; Marek GJ; Seiden LS
    Neurosci Biobehav Rev; 2005; 29(4-5):785-98. PubMed ID: 15893376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans.
    Lile JA; Stoops WW; Durell TM; Glaser PE; Rush CR
    Exp Clin Psychopharmacol; 2006 May; 14(2):136-47. PubMed ID: 16756417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy in long-term treatment of depression.
    Montgomery SA
    J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile.
    Segal DS; Kuczenski R
    J Pharmacol Exp Ther; 1999 Oct; 291(1):19-30. PubMed ID: 10490882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation of learning on stimulant-drug therapy.
    McCabe ER; McCabe L
    N Engl J Med; 1972 Oct; 287(16):825. PubMed ID: 5057561
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of psychomotor stimulants on attentional performance in rats: nicotine, amphetamine, caffeine and methylphenidate.
    Bizarro L; Patel S; Murtagh C; Stolerman IP
    Behav Pharmacol; 2004 May; 15(3):195-206. PubMed ID: 15187577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings: Effect of intravenous d-amphetamine, 1-amphetamine and methylphenidate in schizophrenics.
    Janowski DS; Davis JM; El-Yousef MK
    Psychopharmacol Bull; 1974 Jul; 10(3):15-24. PubMed ID: 4419363
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacological changes of binaural hearing and of vestibular activity].
    Hahn R; Scarzella R
    Minerva Otorinolaringol; 1967; 17(1):21-9. PubMed ID: 5302089
    [No Abstract]   [Full Text] [Related]  

  • 16. Submissive behavior in mice as a test for antidepressant drug activity.
    Malatynska E; Rapp R; Harrawood D; Tunnicliff G
    Pharmacol Biochem Behav; 2005 Oct; 82(2):306-13. PubMed ID: 16185758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant drug selection: criteria and options.
    Preskorn SH
    J Clin Psychiatry; 1994 Sep; 55 Suppl A():6-22; discussion 23-4, 98-100. PubMed ID: 7961544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylphenidate and amphetamine modulate differently the NMDA and AMPA glutamatergic transmission of dopaminergic neurons in the ventral tegmental area.
    Prieto-Gómez B; Vázquez-Alvarez AM; Martínez-Peña JL; Reyes-Vázquez C; Yang PB; Dafny N
    Life Sci; 2005 Jun; 77(6):635-49. PubMed ID: 15921995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bupropion: a review of its mechanism of antidepressant activity.
    Ascher JA; Cole JO; Colin JN; Feighner JP; Ferris RM; Fibiger HC; Golden RN; Martin P; Potter WZ; Richelson E
    J Clin Psychiatry; 1995 Sep; 56(9):395-401. PubMed ID: 7665537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.